Ala Eddin Sagar/LinkedIn
Mar 22, 2026, 16:21
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center – Madinah, shared a post on LinkedIn:
Apixaban or rivaroxaban for acute VTE?
This study is one of three papers discussed in this week’s episode of This Week in Pulmonary and Critical Care Medicine.
We review:
- A randomized trial comparing apixaban vs rivaroxaban for VTE
- An ICU study on oscillatory airway therapy in ventilated patients
- A teaching discussion on how mitral valve disease affects the lungs
Curious how others are interpreting the DOAC trial.
Do you favor apixaban or rivaroxaban for acute VTE?
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs